{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:08:51Z","timestamp":1791554931495,"version":"4.3.4"},"reference-count":26,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2011,5,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> The purpose of this study was to evaluate the impact of carboplatin and paclitaxel in patients with advanced previously untreated thymoma and thymic carcinoma. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> We conducted a prospective multicenter study in patients with unresectable thymoma (n = 21) or thymic carcinoma (n = 23). Patients were treated with carboplatin (area under the curve, 6) plus paclitaxel (225 mg\/m<jats:sup>2<\/jats:sup>) every 3 weeks for a maximum of six cycles. The primary end point of this trial was to evaluate the objective response rate. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> From February 2001 through January 2008, 46 patients were enrolled. Thirteen patients had grade 4 or greater toxicity, mostly neutropenia. Using RECIST (Response Evaluation Criteria in Solid Tumors) 1.0 criteria, three complete responses (CRs) and six partial responses (PRs; objective response rate [ORR], 42.9%; 90% CI, 24.5% to 62.8%) were observed in the thymoma cohort; 10 patients had stable disease. For patients with thymic carcinoma, no CRs and five PRs (ORR, 21.7%; 90% CI, 9.0% to 40.4%) were observed; 12 patients had stable disease. Progression-free survival (PFS) was 16.7 (95% CI, 7.2 to 19.8) and 5.0 (95% CI, 3.0 to 8.3) months for thymoma and thymic carcinoma cohorts, respectively. To date, only seven patients (33.3%) with thymoma have died, compared with 16 patients (69.6%) with thymic carcinoma. Median survival time was 20.0 months (95% CI, 5.0 to 43.6 months) for patients with thymic carcinoma, but it has not been reached for patients with thymoma. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Carboplatin plus paclitaxel has moderate clinical activity for patients with thymic malignancies, but this seems less than expected with anthracycline-based therapy. Patients with thymic carcinoma have poorer PFS and overall survival than patients with thymoma. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2010.32.9607","type":"journal-article","created":{"date-parts":[[2011,4,19]],"date-time":"2011-04-19T04:20:27Z","timestamp":1303186827000},"page":"2060-2065","source":"Crossref","is-referenced-by-count":210,"title":["Phase II Study of Carboplatin and Paclitaxel in Advanced Thymoma and Thymic Carcinoma"],"prefix":"10.1200","volume":"29","author":[{"given":"Girum L.","family":"Lemma","sequence":"first","affiliation":[{"name":"From the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Dana-Farber Cancer Institute, Boston, MA; New Jersey Medical School, Newark, NJ; University of Pennsylvania; Albert Einstein Cancer Center, Philadelphia, PA; and Vanderbilt University, Nashville, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Whei","family":"Lee","sequence":"additional","affiliation":[{"name":"From the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Dana-Farber Cancer Institute, Boston, MA; New Jersey Medical School, Newark, NJ; University of Pennsylvania; Albert Einstein Cancer Center, Philadelphia, PA; and Vanderbilt University, Nashville, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seena C.","family":"Aisner","sequence":"additional","affiliation":[{"name":"From the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Dana-Farber Cancer Institute, Boston, MA; New Jersey Medical School, Newark, NJ; University of Pennsylvania; Albert Einstein Cancer Center, Philadelphia, PA; and Vanderbilt University, Nashville, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey J.","family":"Langer","sequence":"additional","affiliation":[{"name":"From the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Dana-Farber Cancer Institute, Boston, MA; New Jersey Medical School, Newark, NJ; University of Pennsylvania; Albert Einstein Cancer Center, Philadelphia, PA; and Vanderbilt University, Nashville, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Tester","sequence":"additional","affiliation":[{"name":"From the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Dana-Farber Cancer Institute, Boston, MA; New Jersey Medical School, Newark, NJ; University of Pennsylvania; Albert Einstein Cancer Center, Philadelphia, PA; and Vanderbilt University, Nashville, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Johnson","sequence":"additional","affiliation":[{"name":"From the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Dana-Farber Cancer Institute, Boston, MA; New Jersey Medical School, Newark, NJ; University of Pennsylvania; Albert Einstein Cancer Center, Philadelphia, PA; and Vanderbilt University, Nashville, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Sr","given":"Patrick J.","family":"Loehrer","sequence":"additional","affiliation":[{"name":"From the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Dana-Farber Cancer Institute, Boston, MA; New Jersey Medical School, Newark, NJ; University of Pennsylvania; Albert Einstein Cancer Center, Philadelphia, PA; and Vanderbilt University, Nashville, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11099"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(10)62751-8"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s003300050525"},{"key":"B4","first-page":"201","volume":"33","author":"Verstandig AG","year":"1992","journal-title":"Crit Rev Diagn Imaging"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/0003-4975(91)90999-7"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1974.00320200184029"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1164"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.9.3093"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690773"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2003.12.010"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199308000-00014"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyf059"},{"key":"B14","first-page":"145","volume-title":"Pathology and Genetics: Tumors of the Lung, Pleura, Thymus and Heart\u2014WHO Classification of Tumors","author":"Muller-Hermelink HK","year":"2004"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910815)68:4<706::AID-CNCR2820680407>3.0.CO;2-H"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.814"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2009.03.031"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2737"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181db3dee"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyf059"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/BF02989645"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1159\/000097944"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/111.6.826"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(03)00555-1"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2010.32.9607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:10:32Z","timestamp":1653523832000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2010.32.9607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,20]]},"references-count":26,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2011,5,20]]}},"alternative-id":["10.1200\/JCO.2010.32.9607"],"URL":"https:\/\/doi.org\/10.1200\/jco.2010.32.9607","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,20]]}}}